Literature DB >> 7679062

Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on respiratory burst activity of neutrophils in patients with myelodysplastic syndromes.

A Ohsaka1, S Kitagawa, A Yuo, K Motoyoshi, S Furusawa, Y Miura, F Takaku, M Saito.   

Abstract

The superoxide (O2-)-releasing capacity in response to N-formyl-methionyl-leucyl-phenylalanine (FMLP) and the priming effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on FMLP-induced O2- release were investigated in neutrophils from 14 patients with myelodysplastic syndromes (MDS). The O2(-)-releasing capacity in MDS neutrophils varied from patient to patient. As compared with normal neutrophils, the O2(-)-releasing capacity in MDS neutrophils was increased in 9/14 patients, normal in three patients and decreased in two patients. There was no close relationship between the O2(-)-releasing capacity and the peripheral blood neutrophil count or the plasma concentration of C-reactive protein. The priming of neutrophils by rhG-CSF was not observed in five patients, whereas rhGM-CSF primed neutrophils from all patients. The priming effect of rhGM-CSF was consistently greater than that of rhG-CSF in each patient. The intravenous administration of rhG-CSF (300 micrograms/body) to two MDS patients showed an increase in the peripheral blood neutrophil count and enhancement of neutrophil O2- release. These findings demonstrate that the neutrophil O2(-)-releasing capacity in MDS varies from patient to patient and is not always impaired, and that rhGM-CSF is able to prime neutrophils which never respond to rhG-CSF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679062      PMCID: PMC1554685          DOI: 10.1111/j.1365-2249.1993.tb05900.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.

Authors:  L M Souza; T C Boone; J Gabrilove; P H Lai; K M Zsebo; D C Murdock; V R Chazin; J Bruszewski; H Lu; K K Chen; J Barendt; E Platzer; M A S Moore; R Mertelsmann; K Welte
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

2.  Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide.

Authors:  S Kitagawa; A Yuo; L M Souza; M Saito; Y Miura; F Takaku
Journal:  Biochem Biophys Res Commun       Date:  1987-05-14       Impact factor: 3.575

3.  Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival.

Authors:  A F Lopez; D J Williamson; J R Gamble; C G Begley; J M Harlan; S J Klebanoff; A Waltersdorph; G Wong; S C Clark; M A Vadas
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

4.  Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator.

Authors:  R H Weisbart; D W Golde; S C Clark; G G Wong; J C Gasson
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

5.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

6.  Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins.

Authors:  G G Wong; J S Witek; P A Temple; K M Wilkens; A C Leary; D P Luxenberg; S S Jones; E L Brown; R M Kay; E C Orr
Journal:  Science       Date:  1985-05-17       Impact factor: 47.728

7.  Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.

Authors:  S Nagata; M Tsuchiya; S Asano; Y Kaziro; T Yamazaki; O Yamamoto; Y Hirata; N Kubota; M Oheda; H Nomura
Journal:  Nature       Date:  1986 Jan 30-Feb 5       Impact factor: 49.962

8.  Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders.

Authors:  S Martin; S C Baldock; A T Ghoneim; J A Child
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

9.  Blood neutrophil function in primary myelodysplastic syndromes.

Authors:  M A Boogaerts; V Nelissen; C Roelant; W Goossens
Journal:  Br J Haematol       Date:  1983-10       Impact factor: 6.998

10.  Function of neutrophils in preleukaemia.

Authors:  P Ruutu; T Ruutu; P Vuopio; T U Kosunen; A de la Chapelle
Journal:  Scand J Haematol       Date:  1977-04
View more
  3 in total

Review 1.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

2.  Constitutive activation of SHP2 protein tyrosine phosphatase inhibits ICSBP-induced transcription of the gene encoding gp91PHOX during myeloid differentiation.

Authors:  Chunliu Zhu; Stephan Lindsey; Iwonna Konieczna; Elizabeth A Eklund
Journal:  J Leukoc Biol       Date:  2007-12-18       Impact factor: 4.962

3.  Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.

Authors:  Kathleen M Wesa; Susanna Cunningham-Rundles; Virginia M Klimek; Emily Vertosick; Marci I Coleton; K Simon Yeung; Hong Lin; Stephen Nimer; Barrie R Cassileth
Journal:  Cancer Immunol Immunother       Date:  2014-10-29       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.